Oral in capsules or in food; topical as a cream (0.025–0.075%) for pain.
The cream relieves local pain.
View the study (systematic review) →Somewhat reduces appetite and slightly increases energy expenditure.
View the study (meta-analysis) →⏱ 3 min read
Capsaicin is the main pungent alkaloid of the fruits of the genus Capsicum (chili peppers, hot peppers, cayenne peppers, jalapeños, habaneros), responsible for the characteristic burning sensation these fruits produce on contact with mucous membranes; its molecular mechanism is exceptionally well characterized: capsaicin is the prototypical agonist of the TRPV1 receptor (transient receptor potential vanilloid 1 channel), an ion channel that senses heat and inflammation, expressed mainly in afferent sensory neurons specialized in transmitting information about pain, heat, and itch, a pharmacological feature that makes it a privileged tool both for investigating the physiology of pain and for treating it clinically.
The clinical paradox of capsaicin is central to understanding its indications: acute exposure intensely activates TRPV1+ nociceptive fibers, producing the characteristic burning pain sensation, but repeated exposure produces "defunctionalization" of these same fibers (depletion of neurotransmitters such as substance P, receptor internalization, reversible atrophy of cutaneous nerve endings), which results in a sustained loss of nociceptive sensitivity, a mechanism exploited therapeutically to treat several chronic pain conditions poorly managed with other strategies.
The indication with the best clinical support is chronic peripheral neuropathic pain: the 8 percent topical capsaicin formulation (Qutenza), applied in a 30-60 minute session at a specialized clinic, produces significant pain relief that typically lasts 3 months in postherpetic neuralgia, painful diabetic neuropathy, HIV neuropathy, and other neuropathic conditions, an efficacy demonstrated in randomized controlled trials of adequate methodological quality.
Over-the-counter creams and gels with 0.025-0.075 percent capsaicin are an accessible alternative for localized neuropathic pain and arthralgia, with topical applications several times a day for weeks; the effects are gradual and require tolerating the initial burning period until the beneficial defunctionalization of the pain fibers occurs, a feature that significantly reduces clinical adherence, as many patients abandon treatment before obtaining benefit.
In symptomatic osteoarthritis (especially of the hands and knees), creams with 0.025-0.075 percent capsaicin applied 3-4 times a day for weeks significantly reduce pain in the available meta-analyses, with modest but clinically relevant magnitudes for an indication where chronic pain management has limited options, all with their own pharmacological risks.
In the metabolic realm, capsaicin activates brown adipose tissue (with a high density of TRPV1 receptors) and increases resting energy expenditure by modest amounts (50-100 kcal/day with high intakes); the effect on body composition in the long term is very small and clinically marginal in terms of weight loss, although it has a place as a small component of multimodal strategies; specific preparations for oral use (capsiate, capsinoids, less pungent forms) facilitate sustained dosing.
In epidemiological studies, regular consumption of hot chili peppers has been associated with modest reductions in cardiovascular and all-cause mortality; the effects are attributed to multiple mechanisms including modulation of chronic inflammation and improvement of the lipid profile and insulin sensitivity, a population-level indication supported by observational data though not by specific prospective trials.
For topical use against chronic pain, creams at 0.025-0.075 percent applied 3-4 times a day for weeks to months; the 8 percent patch (Qutenza) requires supervised clinical application; for oral use, products usually provide 1-12 mg of capsaicin or capsinoids per dose, with modest thermogenic effects; habitual dietary consumption of chili peppers (several times a week) can provide population-level benefits without the need for specific supplementation.
Generally well tolerated in topical and oral use at nutritional doses; the most frequent adverse effects in topical use are intense initial burning (which is expected and part of the therapeutic mechanism, but limits adherence in many patients), erythema, and pruritus; contact with eyes, mucous membranes, and open wounds should be avoided (it is highly irritating in these areas); hands should be washed carefully after application; with oral use at high doses or in people with gastrointestinal sensitivity, reflux, dyspepsia, abdominal pain, and diarrhea may appear; people with active peptic ulcer, esophagitis, or acute hemorrhoids should moderate dietary consumption; those taking ACE inhibitors may experience exacerbation of the drug-associated cough through interaction with TRPV1 in the airways; pediatric use requires caution because of greater skin sensitivity; in pregnancy and breastfeeding, habitual dietary consumption is safe but the therapeutic use of concentrated creams should be discussed with a clinician.
Information, not medical advice. Scientific evidence reflects the quality of the studies.